SeaCrest Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

SeaCrest Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3	Closed	-$2K	–	1374
2019 Q1	$2K	Sell	3 -20	-87%	-$11.9K	﹤0.01%	1930
2018 Q4	$12K	Hold	23	–	–	﹤0.01%	1438
2018 Q3	$21K	Hold	23	–	–	﹤0.01%	1357
2018 Q2	$17K	Sell	23 -14	-38%	-$16.1K	﹤0.01%	1425
2018 Q1	$58K	Sell	37 -186	-83%	-$240K	0.01%	891
2017 Q4	$200K	Buy	+223	New	+$132K	0.04%	491

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

SeaCrest Wealth Management's NKTR Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Nektar Therapeutics (NKTR) in Q2 2019, closing a stake of 3 shares — an estimated $2K sold.

SeaCrest Wealth Management first reported a position in NKTR in Q4 2017 and held it in 6 quarters. The position peaked at $200K in Q4 2017. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

SeaCrest Wealth Management reported no remaining Nektar Therapeutics position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 3 Nektar Therapeutics shares in Q2 2019, an estimated $2K.
SeaCrest Wealth Management first reported a position in Nektar Therapeutics in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Nektar Therapeutics position peaked at $200K in Q4 2017.
336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.